Chemotherapy in Advanced Bladder Cancer: Current Status and Future
Author Information
Author(s): Ismaili Nabil, Amzerin Mounia, Flechon Aude
Hypothesis
The review aims to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder.
Conclusion
Chemotherapy remains a major treatment option for advanced bladder cancer, with cisplatin-based regimens being the standard for eligible patients.
Supporting Evidence
- Bladder cancer is the seventh most common cancer and the ninth leading cause of cancer deaths in men.
- Cisplatin-based chemotherapy is the standard treatment for patients with good performance status and renal function.
- Chemotherapy has shown limited progress in bladder TCC, with MVAC being the most used regimen for years.
- New drugs and targeted therapies are in development to improve treatment outcomes.
Takeaway
This study talks about how chemotherapy helps treat bladder cancer, especially when it has spread. It shows that certain medicines work better than others.
Methodology
The literature review was conducted using PUBMED and included Phase III trials and important Phase II trials from January 1980 to July 2011.
Limitations
The review does not discuss neoadjuvant or adjuvant chemotherapy and focuses primarily on metastatic transitional cell carcinoma.
Participant Demographics
Bladder cancer predominantly affects males, with a male/female ratio of 3:1, and the average age of diagnosis is 65 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website